Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNUG01 in ALS
NCT06645197Phase 1Not yet recruiting
- Sponsor
- Peking University Third Hospital
- Start
- Oct 2024
- Primary completion
- Apr 2025
- Modality
- Gene Editing, Gene Silencing, Gene Addition/Replacement
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of SNUG01 in amyotrophic lateral sclerosis (ALS), sponsored by Peking University Third Hospital. Primary endpoint: Safety and tolerability of ascending doses of intrathecally administered SNUG01 at 1 year. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
SNUG01
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT06645197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06645197.